Bariatric/GI Research & Clinical Trials
The Bariatric/GI Research & Clinical Trials at HonorHealth Research Institute is dedicated to improving outcomes and quality of life for patients of all ages.
Our Area of Focus
For over 15 years, the Bariatric and Gastrointestinal Division at HonorHealth Research Institute has grown significantly, advancing care through focused, evidence-based clinical research. Led by experts in bariatric medicine, gastroenterology and metabolic disorders, our team is dedicated to improving outcomes and quality of life for patients of all ages, from pediatric to adult, through innovative drug therapies, device technologies, and procedural advancements.
Our research spans a wide range of conditions, including obesity, diabetes, gastrointestinal malignancies, gastroparesis, acid reflux, and autoimmune and inflammatory diseases. We continue to explore developing therapies through clinical trials, including novel pharmacologic agents, endoscopic and surgical techniques, and device based interventions. These studies offer patients access to cutting-edge treatments and contribute to the development of safer, more effective care strategies.
We are committed to ethical, high quality research that delivers meaningful results for participants and reliable data for our research partners. Through multidisciplinary collaboration across surgical, interventional, and medical specialties, we provide personalized, evidence-based care while driving innovation in gastrointestinal and metabolic health.
Bariatric/GI Care Advances
-
Innovative Therapies
-
Device-Based Interventions
-
Procedural Advancements
-
Specialty Collaboration
-
Comprehensive GI and Metabolic Research
-
Ethical and High-Quality Research
HonorHealth Research Institute’s remarkable achievements in Bariatric/GI research includes:
The Bariatric and Gastrointestinal Division has conducted over 35 carefully selected clinical studies, ensuring access to high quality and advanced care options. Several investigational therapies and devices have achieved FDA approval, reflecting the division’s impact on innovative treatment development.
Bariatric/GI Research Facts and Figures
100 Million+
Over 100 million U.S. adults — about 40% — live with obesity, including 20 million with severe obesity, highlighting the need for targeted, evidence-based interventions.
Our Bariatric/GI Programs
Our division is structured around specialized programs that advance care through novel device trials, first-in-human (Phase I) studies, Phase I–III drug development, and Phase IV trials evaluating expanded indications for approved therapies. Research efforts span key therapeutic areas, including bariatric surgery, weight loss management, metabolic disorders, gastroenterology, and interventional gastroenterology. All programs are designed to serve adult patients, with a focused pediatric research effort in weight management and type 2 diabetes.
